A dual-action antibiotic that kills Clostridioides difficile vegetative cells and inhibits spore germination
Proceedings of the National Academy of Sciences · 16.05.2023 · 120 (20)
DOI: 10.1073/pnas.2304110120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 08.05.2023. Verfasst von Jeshina Janardhanan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556. Hauptthemen laut MEDLINE: Clostridioides, Clostridioides difficile. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, National Institutes of General Medical Sciences.
Abstract (Originalsprache)
Clostridioides difficile infection (CDI) is the most lethal of the five CDC urgent public health treats, resulting in 12,800 annual deaths in the United States alone [ Antibiotic Resistance Threats in the United States, 2019 (2019), www.cdc.gov/DrugResistance/Biggest-Threats.html ]. The high recurrence rate and the inability of antibiotics to treat such infections mandate discovery of new therapeutics. A major challenge with CDI is the production of spores, leading to multiple recurrences of infection in 25% of patients [C. P. Kelly, J. T. LaMont, N. Engl. J. Med. 359 , 1932–1940 (2008)], with potentially lethal consequence. Herein, we describe the discovery of an oxadiazole as a bactericidal anti- C. difficile agent that inhibits both cell-wall peptidoglycan biosynthesis and spore germination. We document that the oxadiazole binds to the lytic transglycosylase SleC and the pseudoprotease CspC for prevention of spore germination. SleC degrades the cortex peptidoglycan, a critical step in the initiation of spore germination. CspC senses germinants and cogerminants. Binding to SleC is with higher affinity than that to CspC. Prevention of spore germination breaks the nefarious cycles of CDI recurrence in the face of the antibiotic challenge, which is a primary cause of therapeutic failure. The oxadiazole exhibits efficacy in a mouse model of recurrent CDI and holds promise in clinical treatment of CDI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556.
- Freimann Life Sciences Center, University of Notre Dame, Notre Dame, IN 46556.
ORCID-Profile: Choon Kim, Yuanyuan Qian, Shahriar Mobashery, Mayland Chang
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- National Institutes of General Medical Sciences
Zitieren
APA
Janardhanan, J., Kim, C., Qian, Y., Yang, J., Meisel, J. E., Ding, D., Speri, E., Schroeder, V. A., Wolter, W. R., Oliver, A. G., Mobashery, S., & Chang, M. (2023). A dual-action antibiotic that kills Clostridioides difficile vegetative cells and inhibits spore germination. Proceedings of the National Academy of Sciences, 120(20). https://doi.org/10.1073/pnas.2304110120
Vancouver
Janardhanan J, Kim C, Qian Y, Yang J, Meisel JE, Ding D, et al. A dual-action antibiotic that kills Clostridioides difficile vegetative cells and inhibits spore germination. Proceedings of the National Academy of Sciences. 2023;120(20). doi:10.1073/pnas.2304110120
BibTeX
@article{Janardhanan2023,
author = {Janardhanan, Jeshina and Kim, Choon and Qian, Yuanyuan and Yang, Jingdong and Meisel, Jayda E and Ding, Derong and Speri, Enrico and Schroeder, Valerie A and Wolter, William R and Oliver, Allen G and Mobashery, Shahriar and Chang, Mayland},
title = {A dual-action antibiotic that kills Clostridioides difficile vegetative cells and inhibits spore germination},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {20},
doi = {10.1073/pnas.2304110120}
}
EUVIMED